Holen Sie sich die Stockscreener-App
49.75
0.48%
-0.24
Handel nachbörslich:
49.51
-0.24
-0.48%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$49.99
Offen:
$49.815
24-Stunden-Volumen:
3.29M
Relative Volume:
1.91
Marktkapitalisierung:
$5.95B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-9.4582
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
+33.20%
1M Leistung:
+36.00%
6M Leistung:
+13.87%
1J Leistung:
-9.36%
1-Tages-Spanne:
$48.93
$51.69
1-Wochen-Bereich:
$35.22
$51.69
52-Wochen-Spanne:
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
49.75 | 5.94B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Using Python tools to backtest Cytokinetics Incorporated strategiesJuly 2025 Sector Moves & Weekly Market Pulse Updates - Newser
Spinal Muscular Atrophy Market Positioned for Accelerated - openPR.com
How to read the order book for Cytokinetics Incorporated2025 Short Interest & Community Consensus Picks - Newser
How to manage a losing position in Cytokinetics IncorporatedJuly 2025 News Drivers & Proven Capital Preservation Tips - Newser
Movement Recap: Is Cytokinetics Incorporated a top pick in the sector2025 Trading Volume Trends & AI Based Trade Execution Alerts - khodrobank.com
Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising - MSN
Cytokinetics Incorporated stock prediction for this week2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results - Zacks Investment Research
Cytokinetics shares fall 1.15% premarket after insider sold shares worth $337,800. - AInvest
Is Cytokinetics Incorporated stock bottoming outMarket Performance Summary & Long-Term Capital Growth Strategies - Newser
Will Cytokinetics Incorporated benefit from rate cutsInsider Selling & Risk Controlled Stock Alerts - khodrobank.com
Understanding Cytokinetics Incorporated’s price movement2025 Biggest Moves & Community Trade Idea Sharing Platform - Newser
Does Cytokinetics Incorporated show high probability of reboundJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - Newser
Predicting Cytokinetics Incorporated trend using moving averagesGDP Growth & Safe Entry Trade Reports - Newser
Can Cytokinetics Incorporated recover in the next quarterMarket Rally & Free Safe Capital Growth Stock Tips - Newser
Is Cytokinetics Incorporated’s ROE strong enoughMarket Sentiment Review & AI Driven Stock Price Forecasts - khodrobank.com
Applying chart zones and confluence areas to Cytokinetics Incorporated2025 Year in Review & Growth Oriented Trade Recommendations - Newser
What’s next for Cytokinetics Incorporated stock pricePortfolio Profit Report & Long-Term Growth Plans - Newser
Technical signs of recovery in Cytokinetics IncorporatedMarket Sentiment Summary & Safe Entry Zone Tips - Newser
Detecting support and resistance levels for Cytokinetics IncorporatedChart Signals & High Win Rate Trade Alerts - Newser
How high can Cytokinetics Incorporated stock goJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - Newser
Real time social sentiment graph for Cytokinetics IncorporatedTrade Risk Report & Low Drawdown Trading Techniques - Newser
Cytokinetics’ Aficamten with breakthrough Phase III results - European Biotechnology Magazine
Cytokinetics Shares Jump 40.45% on Aficamten HCM Data $630M Volume Ranks 162nd - AInvest
Is Cytokinetics Incorporated on track to beat earnings2025 Key Highlights & Smart Swing Trading Techniques - khodrobank.com
Should I buy Cytokinetics Incorporated stock nowIPO Watch & Daily Profit Maximizing Trade Tips - khodrobank.com
Cytokinetics’ Aficamten Shows Head-To-Head Advantage Vs. Beta Blockers - insights.citeline.com
Growth or Bubble? Decoding Cytokinetics’ Surge - timothysykes.com
Nvidia, PepsiCo, Tesla, Kraft Heinz, Constellation Brands, Cytokinetics, and More Market Movers - Barron's
Cytokinetics at Citi’s Biopharma Conference: Aficamten’s Promising Path - Investing.com
Cytokinetics Skyrockets On 'Provocative' Results In Heart Disease - Investor's Business Daily
Aficamten Bests Metoprolol in Cytokinetics' Trial for Obstructive Hypertrophic Cardiomyopathy - PharmTech
Bitcoin gains, Frontier upgraded, Cytokinetics trial results - Yahoo Finance
Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK) - Seeking Alpha
Stifel raises Cytokinetics stock price target to $96 on bullish outlook - Investing.com
Cytokinetics says heart disease drug more effective than standard-of-care, shares jump - TradingView
Cytokinetics’ Aficamten: Navigating Regulatory Hurdles and Market Potential in the OHCM Space - AInvest
Cytokinetics Appoints New Director Amid Revenue Boost and Strategic Moves - StocksToTrade
Board Appointment Boosts Cytokinetics’ Growth Projections - timothysykes.com
Cytokinetics Shares are Jumping. Its Heart Drug Looks Better than Ever - Barron's
Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action? - Benzinga
Will Cytokinetics Incorporated face regulatory challengesWeekly Investment Summary & Precise Buy Zone Identification - khodrobank.com
Cytokinetics stock soars after impressive heart drug data By Investing.com - Investing.com Canada
Cytokinetics makes its case for heart-failure drug ahead of FDA decision, stock surges more than 40% - The Business Journals
Cytokinetics shares surge 35.66% in premarket after positive results from MAPLE-HCM III trial. - AInvest
Cytokinetics Soars 35.13% on Promising Heart Disease Data - AInvest
Fed Watch: Is Cytokinetics Incorporated a top pick in the sectorCEO Change & Safe Investment Capital Preservation Plans - خودرو بانک
Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough - Stocktwits
Is Cytokinetics Incorporated forming a reversal patternJuly 2025 Review & Safe Capital Investment Plans - Newser
Pattern recognition hints at Cytokinetics Incorporated upside2025 Top Gainers & Free Weekly Watchlist of Top Performers - Newser
Multi asset correlation models including Cytokinetics IncorporatedQuarterly Trade Summary & Step-by-Step Trade Execution Guides - Newser
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):